Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia
The South East Asia Infectious Disease Clinical Research Network convened subject matter experts at a workshop to make consensus recommendations for study design of a clinical trial for use of intravenous immunoglobulin (IVIg) in severe hand, foot and mouth disease (HFMD). HFMD is a highly contagious emerging infection among children in the region, a small proportion of whom develop neurologic and cardiopulmonary complications with high case-fatality rates. The use of IVIg for treatment of severe disease is widespread and a part of local, national, and international guidelines, but no clinical evidence warrants the use of this drug, which is expensive and has potentially serious side effects. During a 2-day workshop in March 2014, a group of HFMD experts reviewed the current evidence related to use of IVIg in HFMD and discussed potential study design, feasibility, inclusion and exclusion criteria, sample size, primary and secondary endpoints, and subsidiary studies for a randomized, placebo-controlled trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 21(2015), 1 vom: 14. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chea, Sokkosal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Consensus Development Conference |
|---|
| Anmerkungen: |
Date Completed 10.09.2015 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2101.140992 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244794820 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244794820 | ||
| 003 | DE-627 | ||
| 005 | 20231224135453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2101.140992 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM244794820 | ||
| 035 | |a (NLM)25531166 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chea, Sokkosal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2015 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The South East Asia Infectious Disease Clinical Research Network convened subject matter experts at a workshop to make consensus recommendations for study design of a clinical trial for use of intravenous immunoglobulin (IVIg) in severe hand, foot and mouth disease (HFMD). HFMD is a highly contagious emerging infection among children in the region, a small proportion of whom develop neurologic and cardiopulmonary complications with high case-fatality rates. The use of IVIg for treatment of severe disease is widespread and a part of local, national, and international guidelines, but no clinical evidence warrants the use of this drug, which is expensive and has potentially serious side effects. During a 2-day workshop in March 2014, a group of HFMD experts reviewed the current evidence related to use of IVIg in HFMD and discussed potential study design, feasibility, inclusion and exclusion criteria, sample size, primary and secondary endpoints, and subsidiary studies for a randomized, placebo-controlled trial | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Cheng, Yi-Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Chokephaibulkit, Kulkanya |e verfasserin |4 aut | |
| 700 | 1 | |a Chotpitayasunondh, Tawee |e verfasserin |4 aut | |
| 700 | 1 | |a Rogier van Doorn, H |e verfasserin |4 aut | |
| 700 | 1 | |a Hafy, Zen |e verfasserin |4 aut | |
| 700 | 1 | |a Kawichai, Surinda |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ching-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Nguyen Tran |e verfasserin |4 aut | |
| 700 | 1 | |a Ooi, Mong How |e verfasserin |4 aut | |
| 700 | 1 | |a Wolbers, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Mei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 21(2015), 1 vom: 14. Jan. |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2015 |g number:1 |g day:14 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2101.140992 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2015 |e 1 |b 14 |c 01 | ||